Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
26 Results for "
SW48
" in MedChemExpress (MCE) Product Catalog:
Products (26)
26 Results for "SW48" in MCE Product Catalog:
Cat. No.: HY-W1011921
CAS No.: 2227460-99-1
Research Areas:
TDO2-IN-3 is a selective TDO2 inhibitor with an IC50 of 0.34 μM. TDO2-IN-3 can be used in cancer-related research .
Cat. No.: HY-184427
Target:
Research Areas:
WRN-IN-27 is a potent, selective and orally active Werner syndrome RecQ helicase (WRN) inhibitor. WRN-IN-27 inhibits WRN with IC50 values of 20.0 nM and 43.2 nM in the ADP-Glo kinase assay and fluorometric helicase assay, respectively. WRN-IN-27 inhibits MSI-H cell growth selectively (GI50 = 61.8-440 nM), and exhibits antitumor activity in the colon cancer model for MSI-H tumor research .
Cat. No.: HY-183774
CAS No.: 2750027-59-7
Target:
Research Areas:
NTQ2494 is a potent and orally active AXL kinase inhibitor with an IC50 of 4.89 nM. NTQ2494 inhibits AXL kinase catalytic activity. NTQ2494 suppresses tumor growth in mouse xenograft models. NTQ2494 can be used for the research of advanced hematological malignancies, solid tumors .
Cat. No.: HY-110374R
CAS No.: 1992047-61-6
Research Areas:
NVS-CECR2-1 (Standard) is the analytical standard of NVS-CECR2-1 (HY-110374). This product is intended for research and analytical applications. NVS-CECR2-1, a non-BET family Bromodomain (BRD) inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (CECR2) inhibitor. NVS-CECR2-1 binds to CECR2 BRD with high affinity (IC50=47 nM; Kd=80 nM). NVS-CECR2-1 exhibits cytotoxic activity and induces apoptosis against various cancer cells by targeting CECR2 as well as via CECR2-independent mechanism . NVS-CECR2-1 is a chemical probe.
Cat. No.: HY-183748
CAS No.: 3082173-75-6
Target:
Research Areas:
Polθ-IN-11 is an orally active DNA polymerase θ (Polθ) ATPase inhibitor with an IC50 of 4.3 nM against human targets. Polθ-IN-11 activates the cGAS-STING pathway. Polθ-IN-11 upregulates the expression of PD-L1 in HR-deficient cancer cells. Polθ-IN-11 acts synergistically with PARP inhibition in HR-deficient cancer cells and in vivo xenograft models. Polθ-IN-11 can be used in studies related to HR-deficient cancers .
Cat. No.: HY-181562
CAS No.: 3113010-46-8
Target:
Research Areas:
WRN-IN-24 is an orally active allosteric covalent Werner syndrome helicase (WRN) inhibitor with an IC50 of 201 nM. WRN-IN-24 binds to a novel allosteric cavity, forms an additional hydrogen bond with K894, and functionally inhibits WRN activity. WRN-IN-24 inhibits colorectal cancer cells proliferation and exerts dose-dependent antitumor activity in xenograft mouse models. WRN-IN-24 can be used for the research of microsatellite instability-high cancers, including colorectal cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
